Literature DB >> 15975076

The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

Silke Vogelgesang1, Rolf W Warzok, Ingolf Cascorbi, Christiane Kunert-Keil, Eike Schroeder, Heyo K Kroemer, Werner Siegmund, Lary C Walker, Jens Pahnke.   

Abstract

It has been shown in vitro that beta-amyloid (Abeta) is transported by P-glycoprotein (P-gp). Previously, we demonstrated that Abeta immunoreactivity is significantly elevated in brain tissue of individuals with low expression of P-gp in vascular endothelial cells. These findings led us to hypothesize that P-gp might be involved in the clearance of Abeta in normal aging and particularly in Alzheimer's disease (AD). As we were interested in the early pathogenesis of Abeta deposition, we studied the correlation between cerebral amyloid angiopathy (CAA) and P-gp expression in brain tissue samples from 243 non-demented elderly cases (aged 50 to 91 years). We found that endothelial P-gp and vascular Abeta were never colocalized, i.e., vessels with high P-gp expression showed no Abeta deposition in their walls, and vice versa. Abeta deposition occurred first in arterioles where P-gp expression was primarily low, and disappeared completely with the accumulation of Abeta. At this early stage, P-gp was upregulated in capillaries, suggesting a compensatory mechanism to increase Abeta clearance from the brain. Capillaries were usually affected only at later stages of CAA, at which point P-gp was lost even in these vessels. We hypothesize that Abeta clearance may be altered in individuals with diminished P-gp expression due, e.g., to genetic or environmental effects (such as drug administration). The impairment of Abeta clearance could lead to the accumulation and earlier deposition of Abeta, both in the walls of blood vessels and in the brain parenchyma, thus elevating the risk of CAA and AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15975076      PMCID: PMC2763541          DOI: 10.2174/1567205043332225

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  31 in total

Review 1.  The physiological function of drug-transporting P-glycoproteins.

Authors:  A H Schinkel
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

Review 2.  Translating cell biology into therapeutic advances in Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

3.  Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly.

Authors:  L C Walker; J Pahnke; M Madauss; S Vogelgesang; A Pahnke; E W Herbst; D Stausske; R Walther; C Kessler; R W Warzok
Journal:  Acta Neuropathol       Date:  2000-07       Impact factor: 17.088

4.  Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.

Authors:  K Westphal; A Weinbrenner; T Giessmann; M Stuhr; G Franke; M Zschiesche; R Oertel; B Terhaag; H K Kroemer; W Siegmund
Journal:  Clin Pharmacol Ther       Date:  2000-07       Impact factor: 6.875

5.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

6.  Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly.

Authors:  R W Warzok; C Kessler; G Apel; A Schwarz; R Egensperger; D Schreiber; E W Herbst; E Wolf; R Walther; L C Walker
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-03       Impact factor: 2.703

7.  Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.

Authors:  T Gramatté; R Oertel
Journal:  Clin Pharmacol Ther       Date:  1999-09       Impact factor: 6.875

8.  Cerebral amyloid angiopathy in dementia and old age.

Authors:  M M Esiri; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 10.  Pathogenesis of cerebral amyloid angiopathy.

Authors:  Annemieke A M Rensink; Robert M W de Waal; Berry Kremer; Marcel M Verbeek
Journal:  Brain Res Brain Res Rev       Date:  2003-10
View more
  58 in total

1.  Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.

Authors:  Anika M S Hartz; Björn Bauer; Emma L B Soldner; Andrea Wolf; Sandra Boy; Roland Backhaus; Ivan Mihaljevic; Ulrich Bogdahn; Hans H Klünemann; Gerhard Schuierer; Felix Schlachetzki
Journal:  Stroke       Date:  2011-11-23       Impact factor: 7.914

2.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

3.  Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.

Authors:  Loqman A Mohamed; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2016-01-15

Review 4.  Disease-modifying therapies in Alzheimer's disease: how far have we come?

Authors:  Michael Hüll; Mathias Berger; Michael Heneka
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 6.  Impaired mitochondrial energy production and ABC transporter function-A crucial interconnection in dementing proteopathies of the brain.

Authors:  Jens Pahnke; Christina Fröhlich; Markus Krohn; Toni Schumacher; Kristin Paarmann
Journal:  Mech Ageing Dev       Date:  2013-09-03       Impact factor: 5.432

7.  Vascular neural network phenotypic transformation after traumatic injury: potential role in long-term sequelae.

Authors:  J Badaut; G J Bix
Journal:  Transl Stroke Res       Date:  2013-11-29       Impact factor: 6.829

8.  Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET.

Authors:  Viktoria Zoufal; Thomas Wanek; Markus Krohn; Severin Mairinger; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Pekar; Martin Bauer; Jens Pahnke; Oliver Langer
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-24       Impact factor: 6.200

9.  Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature.

Authors:  Edward K Agyare; Sarah R Leonard; Geoffry L Curran; Caroline C Yu; Val J Lowe; Anant K Paravastu; Joseph F Poduslo; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2013-03-05       Impact factor: 4.939

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.